Arbutus Biopharma
Tracked across 3 events · 23 articles · First seen Mar 03, 2026 · Last active Mar 04, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Arbutus Biopharma Corporation is a co-beneficiary of the $2.25 billion settlement with Moderna, receiving a share of the upfront and contingent payments. This settlement acknowledges Arbutus Biopharma Corporation's pivotal contribution to LNP delivery technology. The company is evaluating a return of capital to shareholders.
Mar 03, 2026 · 8 articles
Business
Arbutus Biopharma will receive a substantial payment from Moderna as part of the patent settlement, resolving their claims regarding LNP technology. This positive development led to an 11% rise in its shares.
Mar 03, 2026 · 8 articles
Business
Arbutus Biopharma is a recipient of the settlement payment from Moderna, which could be up to $2.25 billion. This resolves legal actions regarding its lipid nanoparticle technology.
Mar 04, 2026 · 7 articles
Roivant Sciences===Genevant Sciences
exclusive licensee
↔
Arbutus Biopharma
Arbutus Biopharma Corporation is an exclusive licensee of Roivant Sciences===Gen
BioNTech
litigation target
↔
Arbutus Biopharma
BioNTech is currently in ongoing patent litigation with Arbutus Biopharma Corpor
NEWSDESK
Track Arbutus Biopharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard